For this episode of The End Podcast, Biorce CEO Pedro Coelho sits down with Edwin Moses, former CEO of Ablynx, who led the company for over 12 years — scaling it from a small R&D-focused team into a 500-person biotech before its $4.8B acquisition by Sanofi.

They talk about what responsible scaling really demands when science, capital, and patients are all on the line.

They discuss:

 • What are the capabilities a biotech need in order to scale

 • How to make long-term decisions under investor pressure

 • What leadership looks like during and after an exit

 • Why responsibility compounds with experience

In biotech, scale without discipline doesn’t last. That’s the standard we believe in.